July 26th 2024
The CAR T-cell therapy UCART22 has been granted orphan drug designation and rare pediatric drug designation from the FDA for the treatment of acute lymphoblastic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Interpreting Safety and Efficacy Data for Tagraxofusp in BPDCN
November 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, moderated discussion of physicians' familiarity with diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.
Read More
Promising Road Lies Ahead for Bispecific Antibody Combinations in Hematologic Malignancies
November 7th 2023As a monotherapy, bispecific antibodies have demonstrated antitumor activity in heavily pretreated patients with B-cell and T-cell hematologic malignancies, but much work is needed to determine the optimal setting.
Read More
Bhatt Recaps Trial of Ruxolitinib in Steroid Refractory Sclerotic cGVHD
November 4th 2023Vijaya Raj Bhatt, MBBS, MS, discusses background and findings from a multicenter, phase 2 study of ruxolitinib for the treatment of patients with steroid refractory sclerotic chronic graft-versus-host disease.
Watch
Diagnostic Approaches for Hematologic Malignancies With Skin Symptoms
October 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, asked physicians about their experiences with patients with hematological malignancies with skin manifestations, and how to diagnose and work up these patients. This is the first of 2 articles based on this event.
Read More
Practical Tips for Diagnosing and Treating BPDCN
October 19th 2023James Foran, MD, offers valuable insights on recognizing and treating blastic plasmacytoid dendritic cell neoplasm, emphasizing the importance of early diagnosis, collaboration with specialists, and staying informed about therapeutic advances.
Watch
Treatment Sequencing for BPDCN: Expert Insights and Strategies
October 19th 2023Expert perspectives on the sequencing of treatment options for blastic plasmacytoid dendritic cell neoplasm, considering patient age, response to tagraxofusp, venetoclax-based therapies, clinical trials, and future possibilities for targeted agents.
Watch
Managing Capillary Leak Syndrome and Adverse Events in BPDCN Treatment
October 19th 2023Expert perspectives on the sequencing of treatment options for blastic plasmacytoid dendritic cell neoplasm, considering patient age, response to tagraxofusp, venetoclax-based therapies, clinical trials, and future possibilities for targeted agents.
Watch
Understanding How BPDCN Manifests in Clinical Practice
October 19th 2023A key opinion leader identifies the clinical manifestations and diagnostic markers of blastic plasmacytoid dendritic cell neoplasm, shedding light on its presentation and diagnostic significance in real-world medical settings.
Watch
Patient Case: An 87-Year-Old Man With Blastic Plasmacytoid Dendritic Cell Neoplasm
October 19th 2023Expert James Foran, MD, discusses the challenging case of an 87-year-old patient diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), its diagnosis, and treatment options, highlighting the unique considerations for elderly individuals.
Watch
Study Supports Daratumumab Use in R/R Multiple Myeloma
October 18th 2023While there was no significant difference in overall survival between the daratumumab and control groups, safety profile results and follow-up data support daratumumab’s continued evaluation in relapsed/refractory multiple myeloma.
Read More
Pemmaraju Discusses Development of Targeted Therapy for BPDCN
September 25th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, explained the research he and others conducted leading to the development of tagraxofusp-erzs to treat patients with blastic plasmacytoid dendritic cell neoplasm.
Read More